ANTH (Anthera Pharmaceuticals) Inventory Turnover: 0.00 (As of Mar. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Anthera Pharmaceuticals Inventory Turnover?

Anthera Pharmaceuticals ANTH Inventory Turnover is 0.00 as of Mar. 2018.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Anthera Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2018 was $0.00 Mil. Anthera Pharmaceuticals's Average Total Inventories for the quarter that ended in Mar. 2018 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Anthera Pharmaceuticals  (OTCPK:ANTH) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Anthera Pharmaceuticals's Days Inventory for the three months ended in Mar. 2018 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2018 )/Cost of Goods Sold (Q: Mar. 2018 )*Days in Period
=0/0*365 / 4
=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Anthera Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2018 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2018 ) / Revenue (Q: Mar. 2018 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Anthera Pharmaceuticals Inventory Turnover Related Terms

Anthera Pharmaceuticals Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Anthera Pharmaceuticals's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthera Pharmaceuticals Inventory Turnover Chart

Anthera Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Anthera Pharmaceuticals Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Anthera Pharmaceuticals Inventory Turnover Calculation

Anthera Pharmaceuticals's Inventory Turnover for the fiscal year that ended in Dec. 2017 is calculated as

Inventory Turnover (A: Dec. 2017 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2017 ) / ((Total Inventories (A: Dec. 2016 ) + Total Inventories (A: Dec. 2017 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

Anthera Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2018 is calculated as

Inventory Turnover (Q: Mar. 2018 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2018 ) / ((Total Inventories (Q: Dec. 2017 ) + Total Inventories (Q: Mar. 2018 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.00 mean?
Anthera Pharmaceuticals (ANTH) has a Inventory Turnover of 0.00 as of Mar. 2018. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Anthera Pharmaceuticals and its competitors.
Is Anthera Pharmaceuticals' Inventory Turnover too high?
Anthera Pharmaceuticals' current Inventory Turnover is 0.00.
How does Anthera Pharmaceuticals' Inventory Turnover compare to TIKRF and CAPS?
Anthera Pharmaceuticals' Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Anthera Pharmaceuticals and its competitors. Anthera Pharmaceuticals's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthera Pharmaceuticals stock overvalued right now?
Anthera Pharmaceuticals (ANTH) has a current Inventory Turnover of 0.00. The current Inventory Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Anthera Pharmaceuticals (ANTH), the current Inventory Turnover is 0.00 as of Mar. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anthera Pharmaceuticals Business Description

Address 700 Milam, Suite 1300, Houston, TX, USA, 77002
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.